Thank you to everyone who attended the Happy Lungs Project 2023 RET Research Update. Below is the link to the recording and a summary of the amazing progress, thanks to your support, in 2023! If you have follow up questions, please feel free to email them to us at firstname.lastname@example.org and we will email the doctor's responses back to you as soon as possible. Wishing you a healthy, happy 2024!happylungsproject.org/2023-ret-cancer-research-update/... See MoreSee Less
Exciting data from the second-generation RET inhibitor EP-0031 by Ellipses Pharma presented at the EORTC-NCI-AACR meeting in Boston 15th of October 2023EP0031 (A400/KL590586), a next generation selective RET inhibitor (SRI), is being developed in parallel in Phase 1/2 studies in China (NCT05265091, Kelun Biotech) and in the West (NCT05443126, Ellipses Pharma).The investigators presented at the EORTC-NCI-AACR meeting results from the results of the ongoing phase I/II study in Western patients that evaluates the safety and efficacy of the next generation selective RET inhibitor EP0031 in patients with advanced RET-altered malignancies.A total of 17 patients were enrolled in the trial, 6 medullary thyroid cancer (MTC), 8 NSCLC, and 3 patients with other tumor types. 10 patients were evaluable for efficacy including 4 NSCLC patients. Encouraging preliminary safety and tolerability profile was observed with no dose-limiting toxicities or treatment-related deaths.EP0031 resulted in stabilization of disease or marked tumor shrinkage and response. Partial responses were observed in 3/3 patients with RET fusion advanced NSCLC previously treated with 1st generation specific RET inhibitors. Complete response observed in 1/1 patient with RET fusion NSCLC naïve to RET inhibitors. The compound also showed intracranial responses in patients naïve to, or previously treated with 1st generation specific RET inhibitors.This clinical trial is ongoing in centers in US and Spain, opening in UK and France, and rapidly expanding to additional sites and countries. Find the poster here and more information about this study, on the clinical trial website NCT05443126, and on Ellipses Pharma website.Here's the link to the poster: ellipses.life/wp-content/uploads/2023/10/B043_AACR_oct23_final.pdf?utm_source=brochures&utm_mediu...Research is hope! ... See MoreSee Less
We are a 501(c)(3) non-profit, patient-driven community. Our mission is to support researchers and clinicians in their work towards finding a cure for RET-Positive Non-Small Cell Lung Cancer, while educating and empowering patients in their own healing journey.